Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$37.9M
12M shares
52-week range
$2.49 – $27.69
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
www.incannex.com.auNo one on the platform currently holds IXHL.
No tracked institution reports a position in IXHL as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-02-27 | 1-for-30reverse |
No one on the platform has traded IXHL yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$IXHL Complete disaster. Now they're screwed. They won't be able to raise any more money for research. The institutions that participated in the offering are deep in the red, and the warrants don't kick in until $6.50. This is a disaster, and this man is destroying the scientific achievements of the staff.
View on StockTwits ↗$IXHL it was evident Joel was killing this and this is the unrelenting evidence of his idiocy. 0.10 CENTS, Folks. Only ⬇️⬇️⬇️⬇️ for a whole year 🤣
View on StockTwits ↗$IXHL I think this mysterious 3.50 candle is a sign where it headed.
View on StockTwits ↗$IXHL well done Joel! You are slowly driving institutional investors away from the company.. some said R/S would attract institutions but it's becoming the opposite. I wonder what your masterplan is.
View on StockTwits ↗$IXHL Is it final day for 13F's today? I wonder if anything interesting shows up?
View on StockTwits ↗$IXHL Excited now theres discussions about the pathways
View on StockTwits ↗$IXHL The Volume in the Premarket is building nicely into the open. The narrative must be resonating with deep pocketed investors. Great work from the team. Mechanisms Pathways
View on StockTwits ↗$IXHL Looks like can still post informative pool side snaps of the 1600% suprise you hiding. Cheers from Fubai Pathways are ready for facilitating
View on StockTwits ↗$IXHL Stocktwits was going well with improvements and now it's messed up the one good feature it offers that people like - Gifs( doesn't work on Android devices) .. did Joel pick up a second job to help them ?
View on StockTwits ↗Fun Friday Watchlist- Bounce Time $GNS $IXHL $BULL $ASST $POET
View on StockTwits ↗Crazy 1,582% Runner $XHG Today, New Video on the Bullish Analysis on $IXHL $GNS $CRML $GCTS and More Analysis for a Run https://www.youtube.com/watch?v=-2wuLByg_Ag
View on StockTwits ↗$IXHL That is correct. Centers come on board little by little gradually over time. Clinical trialsdotgov is an excellent source for this information although it can lag behind a week or two at a time, due to the company or the site not updating in real time. Our next two catalysts still remain... "First patient screened / dosed" (signals the start of active enrollment). "All trial sites activated" (confirms 100% of sites are open for screening). It's been three calendar weeks since the first initial screening on July 22nd. Each day gets us closer to First Dose. NFA. Jmo. Trade for yourselves.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $40M | +5614.3% | $-1.46 | $-1.46–$-1.46 | — | 1 |
| 2028 | $53431 | -99.9% | $-1.85 | $-1.85–$-1.85 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-15 | $-0.60 | $-0.35 | +41.7% |
| 2026-02-13 | $-0.60 | $-0.60 | +0.0% |
| 2025-11-14 | $-11.70 | $-0.60 | +94.9% |
| 2025-09-29 | $-0.00 | $-0.57 | -19451.7% |
| 2025-05-15 | $-13.81 | $-7.21 | +47.8% |
| 2025-02-14 | $-13.20 | $-9.91 | +24.9% |
| 2024-11-14 | $-0.76 | $-10.83 | -1325.0% |
| 2024-09-30 | $-0.72 | $-11.71 | -1535.5% |
| $57M |
| — |
| SEERSeer, Inc. | $2.10 | +0.00% | $115M | — |
Source: Financial Modeling Prep · peers by sector/industry